selective S1PR2 antagonist preclin. candidate

oral efficacy (1 mpk BID) in fibrosis model

scaffold hop from literature starting points

J. Med. Chem., May 3, 2021

Galapagos NV, Mechelen, Belgium


The Galapagos S1PR2 antagonist GLPG2938 is a preclinical candidate intended for the treatment of idiopathic pulmonary fibrosis (IPF). Though several S1PR1 modulators have been approved, no selective S1PR2 antagonist has entered…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: